Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ACR | P10323 | 1/20 | 0.41 |
| ▸ | PPIA | P62937 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.41 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19766798 | 0.93 | MAPT (0.48) | MAPTALDH1A1BRD4HSP90AA1HSP90AB1 | |
| SCHEMBL30985926 | 0.90 | BRD4 (0.46) | MAPTALDH1A1BRD4LMNATHRB | |
| SCHEMBL22529568 | 0.90 | BRD4 (0.46) | MAPTALDH1A1BRD4LMNATHRB | |
| SCHEMBL656781 | 0.88 | BRD4 (0.49) | MAPTALDH1A1BRD4LMNATHRB | |
| SCHEMBL2946510 | 0.87 | MAPT (0.46) | MAPTALDH1A1BRD4LMNAL3MBTL1 | |
| SCHEMBL2945376 | 0.87 | MAPT (0.49) | MAPTALDH1A1BRD4ACRPPIA | |
| SCHEMBL1578001 | 0.87 | MAPT (0.56) | MAPTALDH1A1BRD4L3MBTL1THRB | |
| SCHEMBL28421780 | 0.86 | BRD4 (0.47) | MAPTALDH1A1BRD4HSP90AA1HSP90AB1 | |
| SCHEMBL72220 | 0.85 | BRD4 (0.66) | MAPTALDH1A1BRD4LMNATHRB | |
| SCHEMBL2942190 | 0.85 | MAPT (0.48) | MAPTALDH1A1BRD4ACRPPIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| CN-107540624-B | Heat shock protein inhibitor and preparation method and application thereof | 广州市恒诺康医药科技有限公司 | 2020-06-16 | — | — | CN | disclosed |
| CN-107108591-B | Resorcinol derivatives as HSP90 inhibitors | 正大天晴药业集团股份有限公司 | 2020-05-05 | — | — | CN | disclosed |
| US-10413550-B2 | Isoxazole compounds as inhibitors of heat shock proteins | THE INSTITUTE OF CANCER RESEARCH (GB) | 2019-09-17 | — | — | US | disclosed |
| US-10413550-B2 | Isoxazole compounds as inhibitors of heat shock proteins | THE INSTITUTE OF CANCER RESEARCH (GB) | 2019-09-17 | — | — | US | disclosed |
| US-10035792-B2 | Resorcinol derivative as HSP90 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-07-31 | — | — | US | disclosed |
| US-10035792-B2 | Resorcinol derivative as HSP90 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-07-31 | — | — | US | disclosed |
| US-10035792-B2 | Resorcinol derivative as HSP90 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-07-31 | — | — | US | disclosed |
| US-20180009794-A1 | Resorcinol Derivative As HSP90 Inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-01-11 | — | — | US | disclosed |
| US-20100179138-A1 | Isozazole Compounds As Inhibitors Of Heat Shock Proteins | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-07-15 | — | — | US | disclosed |
| US-20100179138-A1 | Isozazole Compounds As Inhibitors Of Heat Shock Proteins | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-07-15 | — | — | US | disclosed |
| US-7705027-B2 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-04-27 | — | — | US | disclosed |
| US-7705027-B2 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-04-27 | — | — | US | disclosed |
| WO-2009036012-A1 | HSP90 INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20090076006-A1 | HSP90 INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090076006-A1 | HSP90 INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20060241106-A1 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS DEVELOPMENT LIMITED (GB) | 2006-10-26 | — | — | US | disclosed |
| EP-1611112-A1 | ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS | Vernalis (Cambridge) Limited (GB) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004072051-A1 | ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179138-A1 | Isozazole Compounds As Inhibitors Of Heat Shock Proteins | HSP90AB1, HSP90AA1, HSP90AB2P | MAPT 4442/4885ALDH1A1 279/4885BRD4 2216/4885 |
| US-10035792-B2 | Resorcinol derivative as HSP90 inhibitor | HSP90AB1, HSP90AA1, HSP90AB2P | MAPT 74/4885ALDH1A1 1322/4885BRD4 1870/4885 |
| US-20180009794-A1 | Resorcinol Derivative As HSP90 Inhibitor | HSP90AB1, HSP90AA1, HSP90AB2P | MAPT 74/4885ALDH1A1 1322/4885BRD4 1870/4885 |
| US-20060241106-A1 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | MAPT 4314/4885ALDH1A1 380/4885BRD4 2126/4885 |
| US-10413550-B2 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | MAPT 4411/4885ALDH1A1 351/4885BRD4 2399/4885 |
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | MAPT 4418/4885ALDH1A1 350/4885BRD4 2407/4885 |
| US-20090076006-A1 | HSP90 INHIBITORS CONTAINING A ZINC BINDING MOIETY | HSP90AB1, HSP90AB2P, HSP90B1 | MAPT 1584/4885ALDH1A1 1920/4885BRD4 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.